An observational study in Bone Resorption, sponsored by Mohamed Elsawy. Recruiting at 1 site in Egypt. Open to participants aged 55 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-10-23.
Sponsored by Mohamed Elsawy · Observational
. There is little information on the degree of crestal bone loss around 4 inter-foraminal implant-retained mandibular overdentures (OVDs) and the amount of bone remodelling on the anterior maxilla and posterior mandibule on long-term function, particularly with different distributions.
Numerous studies confirm the successful use of implants to retain prostheses in the edentulous atrophic mandible. It has been recommended by some authors that clinicians should use 3 or 4 implants in situations that require increased retention, such as high muscle attachment or prominent mylohyoid ridge. LOCATOR attachment as a retentive component has several advantages over other systems, Such as: dual retention through both external and internal mating surfaces, a self-aligning feature which is helpful in guiding patients when placing their denture. There is little information on the degree of crestal bone loss around 4 inter-foraminal implant-retained mandibular overdentures (OVDs) and the amount of bone remodelling on the anterior maxilla and posterior mandibule on long-term function, particularly with different distributions.
167 studies on the registry are indexed under Bone Resorption; 28 are open to participants now.
This study's planned enrollment of 20 is below the median of 43 across 18 observational studies indexed under Bone Resorption.
Browse Bone Resorption studies →This is the only study on the registry with Mohamed Elsawy as lead sponsor.
Counted across the registry records on this site, refreshed daily.
10 patients in each group. total number of patients 20.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with quadrilateral distribution of implants
Other: observation
Patients with lineardistribution of implants
Other: observation
To compare the effect of the mandibular implant retained OVD using quadrilateral distribution (QD) versus linear distribution (LD) on posterior mandibular ridge resorption (PMandRR), anterior maxillary ridge resorption (AMaxRR), and changes to the crestal bone level around implants after 10 years of function.
Posterior mandibular ridge resorption (PMandRR)
The amount of PMandRR will be assessed using posterior area index on a panoramic x-ray which use specific landmarkds.
Time frame: 10 years retrospective study
Anterior maxillary ridge resorption (AMaxRR)
The amount of PMandRR will be assessed using anterior area index on a panoramic x-ray, which use specific landmarks.
Time frame: 10 years
Crestal bone loss around implants
amount of bone loss which appears on a periapical radiograph.
Time frame: 10 years
Plan to share: No — just by contacting the corresponding author
No publications or documents are linked to this record.
Started Mar 2023 (actual). Primary completion is estimated for Oct 2023, 6 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.